Related Experiment Video
Updated: Aug 28, 2025

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Renalase Challenges the Oxidative Stress and Fibroproliferative Response in COVID-19
Dijana Stojanovic1, Miodrag Stojanovic2,3, Jelena Milenkovic1
1Department of Pathophysiology, Faculty of Medicine, University of Nis, Nis, Serbia.
Insights
Renalase, a kidney-derived enzyme, shows promise in treating COVID-19 by reducing inflammation and fibrosis. This molecule offers organ protection against cell damage, potentially aiding recovery from severe respiratory illness.
Area of Science:
- Immunology and Pathology
- Biochemistry and Molecular Biology
- Pharmacology and Therapeutics
Background:
- Coronavirus disease 2019 (COVID-19) pathophysiology involves uncontrolled immune responses, cytokine storms, and oxidative stress, leading to acute respiratory distress syndrome and fibrosis.
- Current therapeutic strategies for severe COVID-19 focus on anti-inflammatory and antifibrotic treatments to mitigate disease progression and post-infection complications.
- Identifying novel therapeutic targets is crucial for managing the multifaceted pathology of COVID-19.
Purpose of the Study:
- To review the scientific rationale for using renalase in experimental models of COVID-19.
- To explore renalase's potential in targeting acute-phase inflammatory mechanisms and preventing fibrosis progression.
- To highlight renalase as a potential therapeutic agent for COVID-19 based on its cytoprotective properties.
Main Methods:
- Review of experimental evidence on renalase's organ-protective effects.
- Analysis of renalase's molecular pathways, including sirtuin activation and NAD+ level enhancement.
- Examination of renalase's demonstrated efficacy in alleviating experimentally induced organ fibrosis and adverse remodeling.
Main Results:
- Renalase exhibits significant organ protection by mitigating inflammation, oxidative stress, necrosis, and apoptosis.
- Systemic administration of renalase effectively reduces experimentally induced organ fibrosis and prevents adverse remodeling.
- Renalase activates sirtuins by increasing NAD+ levels, indicating a mechanism for cell protection and survival.
Conclusions:
- Renalase's cytoprotective mechanisms, including anti-inflammatory and antifibrotic effects, provide a strong rationale for its investigation in COVID-19 models.
- Targeting acute-phase mechanisms and fibrosis progression with renalase may offer a novel therapeutic approach for severe COVID-19.
- Further research into renalase's employment in experimental COVID-19 models is warranted to exploit its therapeutic potential.
Abstract:
The hallmark of the coronavirus disease 2019 (COVID-19) pathophysiology was reported to be an inappropriate and uncontrolled immune response, evidenced by activated macrophages, and a robust surge of proinflammatory cytokines, followed by the release of reactive oxygen species, that synergistically result in acute respiratory distress syndrome, fibroproliferative lung response, and possibly even death. For these reasons, all identified risk factors and pathophysiological processes of COVID-19, which are feasible for the prevention and treatment, should be addressed in a timely manner. Accordingly, the evolving anti-inflammatory and antifibrotic therapy for severe COVID-19 and hindering post-COVID-19 fibrosis development should be comprehensively investigated. Experimental evidence indicates that renalase, a novel amino-oxidase, derived from the kidneys, exhibits remarkable organ protection, robustly addressing the most powerful pathways of cell trauma: inflammation and oxidative stress, necrosis, and apoptosis. As demonstrated, systemic renalase administration also significantly alleviates experimentally induced organ fibrosis and prevents adverse remodeling. The recognition that renalase exerts cytoprotection via sirtuins activation, by raising their NAD+ levels, provides a "proof of principle" for renalase being a biologically impressive molecule that favors cell protection and survival and maybe involved in the pathogenesis of COVID-19. This premise supports the rationale that renalase's timely supplementation may prove valuable for pathologic conditions, such as cytokine storm and related acute respiratory distress syndrome. Therefore, the aim for this review is to acknowledge the scientific rationale for renalase employment in the experimental model of COVID-19, targeting the acute phase mechanisms and halting fibrosis progression, based on its proposed molecular pathways. Novel therapies for COVID-19 seek to exploit renalase's multiple and distinctive cytoprotective mechanisms; therefore, this review should be acknowledged as the thorough groundwork for subsequent research of renalase's employment in the experimental models of COVID-19.
Related Concept Videos
Regulation of the Unfolded Protein Response
The Unfolded Protein Response
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

